Major US Advisory Committee to Decide on Changing Baby Hepatitis B Vaccine Advisory
Following a postponement and a remarkably divisive session, a government vaccine expert group was set to cast ballots on Friday concerning altering the enduring advisory that every infant be inoculated against hepatitis B.
Intense Discussion and a Postponed Decision
The opening session of the meeting on Thursday was defined by fiery discussion over limiting availability to the hepatitis B vaccine for newborns and a choice to delay the ballot by a day to provide committee members extra time to examine the language. The group, which counsels the Centers for Disease Control and Prevention on vaccination protocols, had put off the vote twice in the past.
“Is there any specific evidence of harm of giving this shot before 30 days? Or is this conjecture?” asked one panel member.
In response, another member stated, “There is scant proof about the prolonged hazard.”
Existing Recommendations and Likely Ramifications
The vaccine is currently recommended for all infants within 24 hours of birth to stop transmission of hepatitis B, which can cause serious liver damage. It has been given to 1.4 billion people for more than three decades.
The Georgia assembly presented no fresh data of injuries resulting from the vaccine. Authorities state any change to the existing hepatitis B immunization timeline could have profound and widespread implications for infant and child health in the United States.
Group Membership and New Appointments
The advisory panel can only make recommendations to the director of the CDC. The committee's composition has experienced alterations this week, with the announcement that the group's former head would depart for an formal position and be replaced by a heart specialist who has been questioning of other inoculations.
The committee includes multiple vaccination critics who align with a aim to revamp – and perhaps, in some cases, eliminate – long-established immunization guidelines.
